Carol J. Soroka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Carol J. Soroka has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- James Lorenzen Boyer
Section of Digestive Diseases and Yale Liver Center, Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA
8 shared publications - Albert Mennone
Yale Liver Center, Yale University School of Medicine, New Haven, CT
4 shared publications - Lee R. Hagey
Department of Medicine, University of California at San Diego, San Diego, CA, USA
3 shared publications James L. Boyer
Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT
2 shared publications- Shi-Ying Cai
Department of Internal Medicine and Liver Center, Yale University School of Medicine, New Haven, CT, USA
2 shared publications - Shuhua Xu
Liver Center, Yale University School of Medicine, New Haven, CT
2 shared publications
Latest Publications
- Open Access
Human Vascularized Bile Duct-on-a Chip: A multi-cellular micro-physiological system for studying Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease in which the bile ducts of the liver become inflamed and scarred. Scarred bile ducts eventually narrow and obstruct and can cause additional liver pathology including liver failure, repeated infections, and tumors. The pathogenesis of PSC remains largely unknown, partly due to difficulty in obtaining cholangiocytes and partly due to a paucity of in vitro models that capture the various factors contributing to disease progression. Here we report the development of a human vascularized bile duct-on-a-chip that models blood vessels and bile ducts structurally and functionally in three dimensions and includes cholangiocytes derived from control and PSC patient tissue and bile. The flow of blood and bile was modeled by perfusion of cell-lined channels, and cholangiocytes and endothelial cells displayed differential responses to perfusion. Normal and PSC cholangiocytes polarized normally, formed mature tight junctions and displayed similar permeability, comparable to ex vivo measurements. The model with PSC cholangiocytes, however, became more inflammatory than the normal under the stimulation of IL-17A, which induced PBMC and differentiated Th17 cells in the vascular channel to transmigrate more through the endothelial layer of the vascular compartment. In sum, this human vascularized bile duct-on-a-chip recapitulated the vascular-biliary interface structurally and functionally and represents a novel multicellular platform to study inflammatory and fibrotic cholangiopathies such as PSC.
Open AccessHuman Vascularized Bile Duct-on-a Chip: A multi-cellular micro-physiological system for studying Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease in which the bile ducts of the liver become inflamed and scarred. Scarred bile ducts eventually narrow and obstruct and can cause additional liver pathology including liver failure, repeated infections, and tumors. The pathogenesis of PSC remains largely unknown, partly due to difficulty in obtaining cholangiocytes and partly due to a paucity of in vitro models that capture the various factors contributing to disease progression. Here we report the development of a human vascularized bile duct-on-a-chip that models blood vessels and bile ducts structurally and functionally in three dimensions and includes cholangiocytes derived from control and PSC patient tissue and bile. The flow of blood and bile was modeled by perfusion of cell-lined channels, and cholangiocytes and endothelial cells displayed differential responses to perfusion. Normal and PSC cholangiocytes polarized normally, formed mature tight junctions and displayed similar permeability, comparable to ex vivo measurements. The model with PSC cholangiocytes, however, became more inflammatory than the normal under the stimulation of IL-17A, which induced PBMC and differentiated Th17 cells in the vascular channel to transmigrate more through the endothelial layer of the vascular compartment. In sum, this human vascularized bile duct-on-a-chip recapitulated the vascular-biliary interface structurally and functionally and represents a novel multicellular platform to study inflammatory and fibrotic cholangiopathies such as PSC.
- Open Access
Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis
The inflammatory response plays an important role in cholestatic liver injury where bile acid (BA) induction of proinflammatory cytokines in hepatocytes is an initial pathophysiologic event. However, the signaling pathways involving BA stimulation of cytokine production remain to be elucidated. In this report, we examined the functional role of the Nuclear Factor of Activated T-cells (NFAT) in BA-induction of inflammatory genes in hepatic cells and cholestatic livers. We found that NFAT isoform c1 and c3 were expressed in human and mouse hepatocytes. When treated with cholestatic levels of BA, both human and mouse hepatocytes but not cholangiocytes increased NFATc3 nuclear translocation, associated with elevated mRNA levels of IL-8, Cxcl2, and Cxcl10 in these cells. Blocking NFAT activation with pathway-specific inhibitors (i.e. cyclosporine A, FK-506, KN-62 and Inca-6) or knocking down Nfatc3, significantly repressed BA-induction of these cytokines in mouse hepatocytes, including Ccl2, Cxcl2, Cxcl10, Icam1 and Egr1. Nuclear expression of NFATc3/Nfatc3 protein was also increased in cholestatic livers after bile duct ligation or in Abcb4 -/- mice and in patients with primary biliary cholangitis and primary sclerosing cholangitis in association with tissue elevations of Cxcl2 and IL-8. Gene reporter assays and ChIP-PCR demonstrated that the NFAT response element in its promoter played a key role in BA-induced human IL-8 expression. Together our findings indicate that NFAT plays an important role in BA stimulation of hepatic cytokines in cholestasis and is a mechanism that may provide novel targets to reduce cholestatic liver injury.
Open AccessHepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis
The inflammatory response plays an important role in cholestatic liver injury where bile acid (BA) induction of proinflammatory cytokines in hepatocytes is an initial pathophysiologic event. However, the signaling pathways involving BA stimulation of cytokine production remain to be elucidated. In this report, we examined the functional role of the Nuclear Factor of Activated T-cells (NFAT) in BA-induction of inflammatory genes in hepatic cells and cholestatic livers. We found that NFAT isoform c1 and c3 were expressed in human and mouse hepatocytes. When treated with cholestatic levels of BA, both human and mouse hepatocytes but not cholangiocytes increased NFATc3 nuclear translocation, associated with elevated mRNA levels of IL-8, Cxcl2, and Cxcl10 in these cells. Blocking NFAT activation with pathway-specific inhibitors (i.e. cyclosporine A, FK-506, KN-62 and Inca-6) or knocking down Nfatc3, significantly repressed BA-induction of these cytokines in mouse hepatocytes, including Ccl2, Cxcl2, Cxcl10, Icam1 and Egr1. Nuclear expression of NFATc3/Nfatc3 protein was also increased in cholestatic livers after bile duct ligation or in Abcb4 -/- mice and in patients with primary biliary cholangitis and primary sclerosing cholangitis in association with tissue elevations of Cxcl2 and IL-8. Gene reporter assays and ChIP-PCR demonstrated that the NFAT response element in its promoter played a key role in BA-induced human IL-8 expression. Together our findings indicate that NFAT plays an important role in BA stimulation of hepatic cytokines in cholestasis and is a mechanism that may provide novel targets to reduce cholestatic liver injury.
- 18 December 2018
- Published by Wolters Kluwer Health in Hepatology
- Vol. 70 (3) , 871-882
Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile
Primary sclerosing cholangitis (PSC) is a heterogeneous and progressive fibroinflammatory cholangiopathy with no known etiology or effective treatment. Studies of PSC are limited due to difficulty in accessing the cholangiocyte, the small percentage of these cells in the liver, instability of in vitro culture systems, and reliance on samples from end‐stage disease. Here, we demonstrate that stem cells can be isolated from the bile of PSC patients undergoing endoscopic retrograde cholangiopancreatography earlier in their clinical course and maintained long term in vitro as three‐dimensional (3D) organoids that express a biliary genetic phenotype. Additionally, bile‐derived organoids (BDOs) can be biobanked and samples obtained longitudinally over the course of the disease. These BDOs express known cholangiocyte markers including gamma glutamyl transferase, cytokeratin 19, epithelial cellular adhesion molecule, cystic fibrosis transmembrane conductance regulator, and anion exchanger 2. RNA sequence analysis identified 39 genes whose expression differed in organoids from PSC patients compared to non‐PSC controls, including human leukocyte antigen DM alpha chain and chemokine (C‐C motif) ligand 20 (CCL20), immune‐related genes previously described in genome‐wide association studies of PSC. Incubation of these BDOs with interleukin 17A or tumor necrosis factor alpha led to an immune‐reactive phenotype with a significant increase in secretion of proinflammatory mediators, including CCL20, a T‐cell chemoattractant. Conclusion: This study demonstrates that bile can be used as a source of biliary‐like cells that can be maintained long term in vitro as 3D organoids; these BDOs retain features of cholangiopathies, including the ability to react to inflammatory stimuli by secreting chemokines and propagating an immune‐reactive phenotype reflective of the pathogenesis of these diseases; thus, BDOs represent a platform for the study of the pathogenesis and therapy of cholangiopathies, particularly PSC.
- 18 December 2018
- Published by Wolters Kluwer Health in Hepatology
- Vol. 70 (3) , 871-882
Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile
Primary sclerosing cholangitis (PSC) is a heterogeneous and progressive fibroinflammatory cholangiopathy with no known etiology or effective treatment. Studies of PSC are limited due to difficulty in accessing the cholangiocyte, the small percentage of these cells in the liver, instability of in vitro culture systems, and reliance on samples from end‐stage disease. Here, we demonstrate that stem cells can be isolated from the bile of PSC patients undergoing endoscopic retrograde cholangiopancreatography earlier in their clinical course and maintained long term in vitro as three‐dimensional (3D) organoids that express a biliary genetic phenotype. Additionally, bile‐derived organoids (BDOs) can be biobanked and samples obtained longitudinally over the course of the disease. These BDOs express known cholangiocyte markers including gamma glutamyl transferase, cytokeratin 19, epithelial cellular adhesion molecule, cystic fibrosis transmembrane conductance regulator, and anion exchanger 2. RNA sequence analysis identified 39 genes whose expression differed in organoids from PSC patients compared to non‐PSC controls, including human leukocyte antigen DM alpha chain and chemokine (C‐C motif) ligand 20 (CCL20), immune‐related genes previously described in genome‐wide association studies of PSC. Incubation of these BDOs with interleukin 17A or tumor necrosis factor alpha led to an immune‐reactive phenotype with a significant increase in secretion of proinflammatory mediators, including CCL20, a T‐cell chemoattractant. Conclusion: This study demonstrates that bile can be used as a source of biliary‐like cells that can be maintained long term in vitro as 3D organoids; these BDOs retain features of cholangiopathies, including the ability to react to inflammatory stimuli by secreting chemokines and propagating an immune‐reactive phenotype reflective of the pathogenesis of these diseases; thus, BDOs represent a platform for the study of the pathogenesis and therapy of cholangiopathies, particularly PSC.
- Open Access
- 25 June 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (4) , 1227-1236
Na+/H+ exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury
The intercellular adhesion molecule 1 (ICAM‐1) is induced in mouse liver after bile duct ligation (BDL) and plays a key role in neutrophil‐mediated liver injury in BDL mice. ICAM‐1 has been shown to interact with cytoskeletal ezrin‐radixin‐moesin (ERM) proteins that also interact with the PDZ protein, Na+/H+ exchanger regulatory factor 1 (NHERF‐1/EBP50). In NHERF‐1−/− mice, ERM proteins are significantly reduced in brush‐border membranes from kidney and small intestine. ERM knockdown reduces ICAM‐1 expression in response to tumor necrosis factor alpha. Here we show that NHERF‐1 assembles ERM proteins, ICAM‐1 and F‐actin into a macromolecule complex that is increased in mouse liver after BDL. Compared to wild‐type (WT) mice, both sham‐operated and BDL NHERF‐1−/− mice have lower levels of activated ERM and ICAM‐1 protein in the liver accompanied by significantly reduced hepatic neutrophil accumulation, serum alanine aminotransferase, and attenuated liver injury after BDL. However, total bile acid concentrations in serum and liver of sham and BDL NHERF‐1−/− mice were not significantly different from WT controls, although hepatic tetrahydroxylated bile acids and Cyp3a11 messenger RNA levels were higher in NHERF‐1−/− BDL mice. Conclusion: NHERF‐1 participates in the inflammatory response that is associated with BDL‐induced liver injury. Deletion of NHERF‐1 in mice leads to disruption of the formation of ICAM‐1/ERM/NHERF‐1 complex and reduction of hepatic ERM proteins and ICAM‐1, molecules that are up‐regulated and are essential for neutrophil‐mediated liver injury in cholestasis. Further study of the role of NHERF‐1 in the inflammatory response in cholestasis and other forms of liver injury should lead to discovery of new therapeutic targets in hepatic inflammatory diseases. (Hepatology 2015;62:1227‐1236)
- 25 June 2015
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (4) , 1227-1236
Open AccessNa+/H+ exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury
The intercellular adhesion molecule 1 (ICAM‐1) is induced in mouse liver after bile duct ligation (BDL) and plays a key role in neutrophil‐mediated liver injury in BDL mice. ICAM‐1 has been shown to interact with cytoskeletal ezrin‐radixin‐moesin (ERM) proteins that also interact with the PDZ protein, Na+/H+ exchanger regulatory factor 1 (NHERF‐1/EBP50). In NHERF‐1−/− mice, ERM proteins are significantly reduced in brush‐border membranes from kidney and small intestine. ERM knockdown reduces ICAM‐1 expression in response to tumor necrosis factor alpha. Here we show that NHERF‐1 assembles ERM proteins, ICAM‐1 and F‐actin into a macromolecule complex that is increased in mouse liver after BDL. Compared to wild‐type (WT) mice, both sham‐operated and BDL NHERF‐1−/− mice have lower levels of activated ERM and ICAM‐1 protein in the liver accompanied by significantly reduced hepatic neutrophil accumulation, serum alanine aminotransferase, and attenuated liver injury after BDL. However, total bile acid concentrations in serum and liver of sham and BDL NHERF‐1−/− mice were not significantly different from WT controls, although hepatic tetrahydroxylated bile acids and Cyp3a11 messenger RNA levels were higher in NHERF‐1−/− BDL mice. Conclusion: NHERF‐1 participates in the inflammatory response that is associated with BDL‐induced liver injury. Deletion of NHERF‐1 in mice leads to disruption of the formation of ICAM‐1/ERM/NHERF‐1 complex and reduction of hepatic ERM proteins and ICAM‐1, molecules that are up‐regulated and are essential for neutrophil‐mediated liver injury in cholestasis. Further study of the role of NHERF‐1 in the inflammatory response in cholestasis and other forms of liver injury should lead to discovery of new therapeutic targets in hepatic inflammatory diseases. (Hepatology 2015;62:1227‐1236)
- 1 June 2014
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 37, 3-14
Biosynthesis and trafficking of the bile salt export pump, BSEP: Therapeutic implications of BSEP mutations
- 1 June 2014
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 37, 3-14
Biosynthesis and trafficking of the bile salt export pump, BSEP: Therapeutic implications of BSEP mutations
- Open Access
- 23 November 2012
- Published by Wolters Kluwer Health in Hepatology
- Vol. 57 (6) , 2418-2426
Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion
The sea lamprey ( Petromyzon marinus ) is a genetically programmed animal model for biliary atresia, as it loses its bile ducts and gallbladder during metamorphosis. However, in contrast to patients with biliary atresia or other forms of cholestasis who develop progressive disease, the postmetamorphosis lampreys grow normally to adult size. To understand how the adult lamprey thrives without the ability to secrete bile, we examined bile salt homeostasis in larval and adult lampreys. Adult livers were severely cholestatic, with levels of bile salts >1 mM, but no evidence of necrosis, fibrosis, or inflammation. Interestingly, both larvae and adults had normal plasma levels (˜10 μM) of bile salts. In larvae, petromyzonol sulfate (PZS) was the predominant bile salt, whereas the major bile salts in adult liver were sulfated C27 bile alcohols. Cytotoxicity assays revealed that PZS was highly toxic. Pharmacokinetic studies in free-swimming adults revealed that ˜35% of intravenously injected bromosulfophthalein (BSP) was eliminated over a 72-hour period. Collection of urine and feces demonstrated that both endogenous and exogenous organic anions, including biliverdin, bile salts, and BSP, were predominantly excreted by way of the kidney, with minor amounts also detected in feces. Gene expression analysis detected marked up-regulation of orthologs of known organic anion and bile salt transporters in the kidney, with lesser effects in the intestine and gills in adults compared to larvae. These findings indicate that adult lampreys tolerate cholestasis by altering hepatic bile salt composition, while maintaining normal plasma bile salt levels predominantly through renal excretion of bile products. Therefore, we conclude that strategies to accelerate renal excretion of bile salt and other toxins should be beneficial for patients with cholestasis.
- 23 November 2012
- Published by Wolters Kluwer Health in Hepatology
- Vol. 57 (6) , 2418-2426
Open AccessAdult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion
The sea lamprey ( Petromyzon marinus ) is a genetically programmed animal model for biliary atresia, as it loses its bile ducts and gallbladder during metamorphosis. However, in contrast to patients with biliary atresia or other forms of cholestasis who develop progressive disease, the postmetamorphosis lampreys grow normally to adult size. To understand how the adult lamprey thrives without the ability to secrete bile, we examined bile salt homeostasis in larval and adult lampreys. Adult livers were severely cholestatic, with levels of bile salts >1 mM, but no evidence of necrosis, fibrosis, or inflammation. Interestingly, both larvae and adults had normal plasma levels (˜10 μM) of bile salts. In larvae, petromyzonol sulfate (PZS) was the predominant bile salt, whereas the major bile salts in adult liver were sulfated C27 bile alcohols. Cytotoxicity assays revealed that PZS was highly toxic. Pharmacokinetic studies in free-swimming adults revealed that ˜35% of intravenously injected bromosulfophthalein (BSP) was eliminated over a 72-hour period. Collection of urine and feces demonstrated that both endogenous and exogenous organic anions, including biliverdin, bile salts, and BSP, were predominantly excreted by way of the kidney, with minor amounts also detected in feces. Gene expression analysis detected marked up-regulation of orthologs of known organic anion and bile salt transporters in the kidney, with lesser effects in the intestine and gills in adults compared to larvae. These findings indicate that adult lampreys tolerate cholestasis by altering hepatic bile salt composition, while maintaining normal plasma bile salt levels predominantly through renal excretion of bile products. Therefore, we conclude that strategies to accelerate renal excretion of bile salt and other toxins should be beneficial for patients with cholestasis.
- Open Access
- 12 December 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 55 (6) , 1901-1911
A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis
The liver-specific bile salt export pump (BSEP) is crucial for bile acid–dependent bile flow at the apical membrane. BSEP, a member of the family of structurally related adenosine triphosphate (ATP)-binding cassette (ABC) proteins, is composed of 12 transmembrane segments (TMS) and two large cytoplasmic nucleotide-binding domains (NBDs). The regulation of trafficking of BSEP to and from the cell surface is not well understood, but is believed to play an important role in cholestatic liver diseases such as primary familial intrahepatic cholestasis type 2 (PFIC2). To address this issue, BSEP endocytosis was studied by immunofluorescence and a cell surface enzyme-linked immunosorbent assay (ELISA) endocytosis reporter system using a chimera of the interleukin-2 receptor α (previously referred to as Tac) and the C-terminal tail of BSEP (TacCterm). An autonomous endocytosis motif in the carboxyl cytoplasmic terminus of BSEP was identified. We define this endocytic motif by site-directed mutagenesis as a canonical tyrosine-based motif 1310YYKLV1314 (Yxxϕ). When expressed in HEK293T cells, TacCterm is constitutively internalized via a dynamin- and clathrin-dependent pathway. Mutation of the Y1310Y1311 amino acids in TacCterm and in full-length human BSEP blocks the internalization. Subsequent sequence analysis reveals this motif to be highly conserved between the closely related ABCB subfamily members that mediate ATP-dependent transport of broad substrate specificity. Conclusion: Our results indicate that constitutive internalization of BSEP is clathrin-mediated and dependent on the tyrosine-based endocytic motif at the C-terminal end of BSEP.
- 12 December 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 55 (6) , 1901-1911
Open AccessA C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis
The liver-specific bile salt export pump (BSEP) is crucial for bile acid–dependent bile flow at the apical membrane. BSEP, a member of the family of structurally related adenosine triphosphate (ATP)-binding cassette (ABC) proteins, is composed of 12 transmembrane segments (TMS) and two large cytoplasmic nucleotide-binding domains (NBDs). The regulation of trafficking of BSEP to and from the cell surface is not well understood, but is believed to play an important role in cholestatic liver diseases such as primary familial intrahepatic cholestasis type 2 (PFIC2). To address this issue, BSEP endocytosis was studied by immunofluorescence and a cell surface enzyme-linked immunosorbent assay (ELISA) endocytosis reporter system using a chimera of the interleukin-2 receptor α (previously referred to as Tac) and the C-terminal tail of BSEP (TacCterm). An autonomous endocytosis motif in the carboxyl cytoplasmic terminus of BSEP was identified. We define this endocytic motif by site-directed mutagenesis as a canonical tyrosine-based motif 1310YYKLV1314 (Yxxϕ). When expressed in HEK293T cells, TacCterm is constitutively internalized via a dynamin- and clathrin-dependent pathway. Mutation of the Y1310Y1311 amino acids in TacCterm and in full-length human BSEP blocks the internalization. Subsequent sequence analysis reveals this motif to be highly conserved between the closely related ABCB subfamily members that mediate ATP-dependent transport of broad substrate specificity. Conclusion: Our results indicate that constitutive internalization of BSEP is clathrin-mediated and dependent on the tyrosine-based endocytic motif at the C-terminal end of BSEP.
- 26 April 2010
- Published by Georg Thieme Verlag KG in Seminars in Liver Disease
- Vol. 30 (02) , 178-185
Organic Solute Transporter, OSTα-OSTβ: Its Role in Bile Acid Transport and Cholestasis
Organic solute transporter alpha-beta (OSTα-OSTβ) is a unique heteromeric transporter localized to the basolateral membrane of epithelial cells involved in sterol transport. It is believed to be the primary bile acid efflux transporter in the intestine of mammals and is therefore essential to bile acid homeostasis and the enterohepatic circulation. First described in the evolutionarily primitive small skate, Leucoraja erinacea, this facilitated transporter requires expression of both subunits for its function. It can transport a variety of bile acids, as well as estrone 3-sulfate, dehydroepiandrosterone 3-sulfate, digoxin, and prostaglandin E2. Expression of both subunits is variable between species and tissues; in humans high expression is noted in the liver, small intestine, kidney, testis, and adrenal gland. OSTα-OSTβ is directly regulated by the bile acid sensing nuclear receptor, farnesoid X receptor (FXR). Furthermore, it is part of the complex regulatory pathway that controls bile acid synthesis and homeostasis. Hepatic OSTα-OSTβ is upregulated in cholestasis in both humans and rodents, where it appears to play a protective role. Additional studies are necessary to determine its role in liver injury, bile acid malabsorption, and lipid and glucose metabolism, as well as a potential protective role for kidney OSTα-OSTβ in cholestasis.
- 26 April 2010
- Published by Georg Thieme Verlag KG in Seminars in Liver Disease
- Vol. 30 (02) , 178-185
Organic Solute Transporter, OSTα-OSTβ: Its Role in Bile Acid Transport and Cholestasis
Organic solute transporter alpha-beta (OSTα-OSTβ) is a unique heteromeric transporter localized to the basolateral membrane of epithelial cells involved in sterol transport. It is believed to be the primary bile acid efflux transporter in the intestine of mammals and is therefore essential to bile acid homeostasis and the enterohepatic circulation. First described in the evolutionarily primitive small skate, Leucoraja erinacea, this facilitated transporter requires expression of both subunits for its function. It can transport a variety of bile acids, as well as estrone 3-sulfate, dehydroepiandrosterone 3-sulfate, digoxin, and prostaglandin E2. Expression of both subunits is variable between species and tissues; in humans high expression is noted in the liver, small intestine, kidney, testis, and adrenal gland. OSTα-OSTβ is directly regulated by the bile acid sensing nuclear receptor, farnesoid X receptor (FXR). Furthermore, it is part of the complex regulatory pathway that controls bile acid synthesis and homeostasis. Hepatic OSTα-OSTβ is upregulated in cholestasis in both humans and rodents, where it appears to play a protective role. Additional studies are necessary to determine its role in liver injury, bile acid malabsorption, and lipid and glucose metabolism, as well as a potential protective role for kidney OSTα-OSTβ in cholestasis.
- Open Access
- 23 December 2009
- Published by Wolters Kluwer Health in Hepatology
- Vol. 51 (1) , 181-190
Mouse Organic Solute Transporter α Deficiency Enhances Renal Excretion of Bile Acids and Attenuates Cholestasis
Organic solute transporter alpha-beta (Ostα-Ostβ) is a heteromeric bile acid and sterol transporter that facilitates the enterohepatic and renal-hepatic circulation of bile acids. Hepatic expression of this basolateral membrane protein is increased in cholestasis, presumably to facilitate removal of toxic bile acids from the liver. In this study, we show that the cholestatic phenotype induced by common bile duct ligation (BDL) is reduced in mice genetically deficient in Ost α. Although Ost α−/− mice have a smaller bile acid pool size, which could explain lower serum and hepatic levels of bile acids after BDL, gallbladder bilirubin and urinary bile acid concentrations were significantly greater in Ost α−/− BDL mice, suggesting additional alternative adaptive responses. Livers of Ost α−/− mice had higher messenger RNA levels of constitutive androstane receptor (Car) than wild-type BDL mice and increased expression of Phase I enzymes ( Cyp7a1 , Cyp2b10 , Cyp3a11 ), Phase II enzymes ( Sult2a1 , Ugt1a1 ), and Phase III transporters ( Mrp2 , Mrp3 ). Following BDL, the bile acid pool size increased in Ost α−/− mice and protein levels for the hepatic basolateral membrane export transporters, multidrug resistance-associated protein 3 (Mrp3) and Mrp4, and for the apical bilirubin transporter, Mrp2, were all increased. In the kidney of Ost α−/− mice after BDL, the apical bile acid uptake transporter Asbt is further reduced, whereas the apical export transporters Mrp2 and Mrp4 are increased, resulting in a significant increase in urinary bile acid excretion. Conclusion: These findings indicate that loss of Ost α provides protection from liver injury in obstructive cholestasis through adaptive responses in both the kidney and liver that enhance clearance of bile acids into urine and through detoxification pathways most likely mediated by the nuclear receptor Car. (Hepatology 2010.)
- 23 December 2009
- Published by Wolters Kluwer Health in Hepatology
- Vol. 51 (1) , 181-190
Open AccessMouse Organic Solute Transporter α Deficiency Enhances Renal Excretion of Bile Acids and Attenuates Cholestasis
Organic solute transporter alpha-beta (Ostα-Ostβ) is a heteromeric bile acid and sterol transporter that facilitates the enterohepatic and renal-hepatic circulation of bile acids. Hepatic expression of this basolateral membrane protein is increased in cholestasis, presumably to facilitate removal of toxic bile acids from the liver. In this study, we show that the cholestatic phenotype induced by common bile duct ligation (BDL) is reduced in mice genetically deficient in Ost α. Although Ost α−/− mice have a smaller bile acid pool size, which could explain lower serum and hepatic levels of bile acids after BDL, gallbladder bilirubin and urinary bile acid concentrations were significantly greater in Ost α−/− BDL mice, suggesting additional alternative adaptive responses. Livers of Ost α−/− mice had higher messenger RNA levels of constitutive androstane receptor (Car) than wild-type BDL mice and increased expression of Phase I enzymes ( Cyp7a1 , Cyp2b10 , Cyp3a11 ), Phase II enzymes ( Sult2a1 , Ugt1a1 ), and Phase III transporters ( Mrp2 , Mrp3 ). Following BDL, the bile acid pool size increased in Ost α−/− mice and protein levels for the hepatic basolateral membrane export transporters, multidrug resistance-associated protein 3 (Mrp3) and Mrp4, and for the apical bilirubin transporter, Mrp2, were all increased. In the kidney of Ost α−/− mice after BDL, the apical bile acid uptake transporter Asbt is further reduced, whereas the apical export transporters Mrp2 and Mrp4 are increased, resulting in a significant increase in urinary bile acid excretion. Conclusion: These findings indicate that loss of Ost α provides protection from liver injury in obstructive cholestasis through adaptive responses in both the kidney and liver that enhance clearance of bile acids into urine and through detoxification pathways most likely mediated by the nuclear receptor Car. (Hepatology 2010.)
- Open Access
- 10 October 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 57
N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta
The organic solute transporter (OSTα-OSTβ) is a heteromeric transporter that is expressed on the basolateral membrane of epithelium in intestine, kidney, liver, testis and adrenal gland and facilitates efflux of bile acids and other steroid solutes. Both subunits are required for plasma membrane localization of the functional transporter but it is unclear how and where the subunits interact and whether glycosylation is required for functional activity. We sought to examine these questions for the human OSTα-OSTβ transporter using the human hepatoma cell line, HepG2, and COS7 cells transfected with constructs of human OSTα-FLAG and OSTβ-Myc.
- 10 October 2008
- Published by Springer Nature in BMC Cell Biology
- Vol. 9 (1) , 57
Open AccessN-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta
The organic solute transporter (OSTα-OSTβ) is a heteromeric transporter that is expressed on the basolateral membrane of epithelium in intestine, kidney, liver, testis and adrenal gland and facilitates efflux of bile acids and other steroid solutes. Both subunits are required for plasma membrane localization of the functional transporter but it is unclear how and where the subunits interact and whether glycosylation is required for functional activity. We sought to examine these questions for the human OSTα-OSTβ transporter using the human hepatoma cell line, HepG2, and COS7 cells transfected with constructs of human OSTα-FLAG and OSTβ-Myc.